Unbiased human genomic characterization of polyglutamine disorder genes to guide biological understanding and therapeutic strategies
Preprint
Abstract
Background: Polyglutamine (polyQ) disorders, such as Huntington disease (HD) and several spinocerebellar ataxias, are severe neurological disorders caused by glutamine codon repeat expansions. These conditions lack effective treatments, with therapeutic research focused on pathogenic gene knockdown. Objectives: We aimed to profile these genes using diverse human genomic data to inform therapeutic strategies by identifying new biology and assessing the potential on-target effects of knocking down these genes. Methods: We conducted an unbiased phenome-wide study to identify human traits and diseases linked to polyQ disorder genes (Open Targets L2G>0.5). Network analyses explored shared trait associations and overlapping biological processes among these genes. Lastly, we assessed the theoretical druggability of polyQ disorder genes using recently identified features predictive of clinical trial success and compared them to repeat expansion (HD) modifier genes. Results: We identified 215 human phenotype/polyQ disorder gene associations from 3,095 studies, indicating potential adverse effects from gene knockdown. Shared trait associations among genes suggested overlapping biological processes despite distinct functions. Drug target profile analysis revealed unfavorable risk profiles for polyQ disorder genes, particularly ATN1 , ATXN1 , ATXN7 , and HTT , due to genomic features such as constraint, molecular interactions, and tissue specificity. PolyQ disorder genes also showed significantly more safety-related risks than HD genetic modifier genes ( P =7.03×10 -3 ). Conclusion: Our analyses emphasize the pleiotropic nature of polyQ disorder genes, highlighting their potential risks as drug targets. These findings reinforce the importance of exploring alternative therapeutic strategies, such as targeting genetic modifier genes, as well as allele-selective approaches, to mitigate these challenges.Keywords
This publication has 51 references indexed in Scilit:
- Long somatic DNA-repeat expansion drives neurodegeneration in Huntington’s diseaseCell, 2025
- Polyglutamine disorders: Pathogenesis and potential drug interventionsLife Sciences, 2024
- Drug development advances in human genetics‐based targetsMedcomm, 2024
- Antisense Oligonucleotide Therapy: From Design to the Huntington Disease ClinicBioDrugs, 2022
- Polyglutamine diseasesCurrent Opinion in Neurobiology, 2022
- The Human Protein Atlas—Spatial localization of the human proteome in health and diseaseProtein Science, 2020
- Update on the Treatment of Ataxia: Medication and Emerging TherapiesNeurotherapeutics, 2020
- Metabolic and Organelle Morphology Defects in Mice and Human Patients Define Spinocerebellar Ataxia Type 7 as a Mitochondrial DiseaseCell Reports, 2019
- Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent EffortsMedicinal Research Reviews, 2016
- DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseasesAnnals of Neurology, 2016